CliffBio
small molecule

ATMEKSI

METHOCARBAMOL

Loss of exclusivityOctober 2044latest FDA-listed patent expiry
CompanyRosemont Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameATMEKSI
Active ingredientMETHOCARBAMOL
Strength750MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2025
Marketing statusRX

Listed patents

PatentExpiresType
12390439October 2044product

More from Rosemont Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ATMEKSI patent cliff — loss of exclusivity October 2044 | CliffBio